

Appl. No. : PCT/JP2005/006019
Filed : March 30, 2005

REMARKS

The claims have been amended to conform with the rules of practice before the U.S. Patent and Trademark Office. The specification has been amended to recite the International Application and priority applications. The word "CLAIMS" has been deleted and substituted by "WHAT IS CLAIMED IS" so that subsequently appearing claims will be the object of a sentence as specified by M.P.E.P. section 608.01(m). As a result of this preliminary amendment, Claims 1, 5-9, and 11-13 have been amended. Support for amendment of claims 5 and 11 to include a pharmaceutically acceptable carrier is found in the present specification at page 14, line 5. Accordingly, Claims 1-16 are presented for examination. No new matter is being added herewith.

Conclusion

Should there be any questions concerning this application, the Examiner is invited to contact the undersigned agent at the telephone number appearing below. Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: Jan. 12, 2006

By: Che S. Chereskin

Che Swyden Chereskin, Ph.D.
Registration No. 41,466
Agent of Record
Customer No. 20,995
(949) 760-0404

2277500
011006